<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005893</url>
  </required_header>
  <id_info>
    <org_study_id>199/15101</org_study_id>
    <secondary_id>UMN-MT-1994-18</secondary_id>
    <secondary_id>UMN-MT-9418</secondary_id>
    <nct_id>NCT00005893</nct_id>
  </id_info>
  <brief_title>Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fairview University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of bone marrow transplantation using matched related&#xD;
      donors in patients with nonmalignant hematologic disorders.&#xD;
&#xD;
      II. Determine the quality of life, absence of adverse effects (e.g., graft versus host&#xD;
      disease and B cell lymphoproliferative disease), and completeness of recovery of their&#xD;
      underlying condition in these patients with this treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive IV or oral busulfan every 6 hours on days -9 to -6;&#xD;
      cyclophosphamide IV on days -5 to -2; anti-thymocyte globulin IV on days -4 to -2; and&#xD;
      allogeneic bone marrow transplantation (BMT) on day 0.&#xD;
&#xD;
      Patients with class 3 thalassemia (liver edge greater than 2 cm below costal margin, a&#xD;
      history of inconsistent chelation, and portal fibrosis) receive a less intensive conditioning&#xD;
      regimen consisting of oral busulfan every 6 hours on days -7 to -4; anti-thymocyte globulin&#xD;
      IV on days -5 to -1 and days 1-5; cyclophosphamide IV on days -3 to -2; and allogeneic BMT on&#xD;
      day 0.&#xD;
&#xD;
      Patients are followed at day 28, and then at 3, 6, 12, and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Neutropenia</condition>
  <condition>Sickle Cell Anemia</condition>
  <condition>Thalassemia Major</condition>
  <condition>Red-Cell Aplasia, Pure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Severe hemoglobinopathy including, but not limited to the following:&#xD;
&#xD;
        Homozygous beta thalassemia Other beta chain mutation as demonstrated by hemoglobin&#xD;
        electrophoresis Sickle cell anemia (age 16 to 50 years) Evidence of one or more the&#xD;
        following prior complications: Stage I-II sickle cell lung disease Sickle cell nephropathy&#xD;
        (moderate to severe proteinuria or glomerular filtration rate of 30-50% predicted normal&#xD;
        for age) Acute chest syndrome requiring blood transfusions More than 3 debilitating pain&#xD;
        episodes per year for 3 years lasting more than 4 hours each Any combination of episodes of&#xD;
        acute chest syndrome and painful episodes adding up to 3 episodes per year for 3&#xD;
        consecutive years Requirement for chronic transfusions with alloimmunization (more than 2&#xD;
        antibodies) Sickle cell anemia (age under 16 years) Evidence of one or more the following&#xD;
        prior complications: Prior stroke or hemorrhage Any neurologic event lasting more than 24&#xD;
        hours Abnormal cerebral MRI and cerebral arteriogram MRI angiographic impaired&#xD;
        neuropsychologic testing Stage I-II sickle cell lung disease Sickle cell nephropathy&#xD;
        (moderate to severe proteinuria or glomerular filtration rate of 30-50% predicted normal&#xD;
        for age) Significant visual impairment in at least one eye with bilateral proliferative&#xD;
        retinopathy Acute chest syndrome with history of recurrent hospitalizations or exchange&#xD;
        transfusions Osteonecrosis of multiple joints with destructive changes More than 3&#xD;
        debilitating pain episodes per year or priapism Requirement for chronic transfusions with&#xD;
        alloimmunization&#xD;
&#xD;
        OR&#xD;
&#xD;
        Bone marrow failure syndrome unresponsive to therapy, including but not limited to the&#xD;
        following: Congenital pure red cell aplasia (Diamond Blackfan anemia) Confirmed by bone&#xD;
        marrow aspirate More than 6 transfusions per year despite steroid therapy Kostmann's&#xD;
        neutropenia Confirmed by bone marrow aspirate Unable to maintain absolute neutrophil count&#xD;
        greater than 750/mm3 or recurrent life threatening infections or more than 4&#xD;
        hospitalizations per year despite therapy with filgrastim (G-CSF) No myelodysplasia or&#xD;
        aplastic anemia&#xD;
&#xD;
        Must have a related donor with at least a 5 out of 6 HLA antigen match&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Age: Sickle cell anemia patients 0 to 50; All other patients under 18&#xD;
&#xD;
        Performance status: Karnofsky 70-100%&#xD;
&#xD;
        Hepatic: Bilirubin no greater than 3.0 mg/dL with a direct fraction no greater than 2.0&#xD;
        mg/dL ALT no greater than 150 U/L No moderate or severe portal fibrosis No active hepatitis&#xD;
&#xD;
        Renal: Glomerular filtration rate at least 30% predicted (except with sickle cell anemia)&#xD;
        No renal dysfunction&#xD;
&#xD;
        Cardiovascular: Left ejection fraction at least 50% No cardiac compromise&#xD;
&#xD;
        Other: No severe, stable neurologic impairment HIV negative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J. Orchard</last_name>
    <role>Study Chair</role>
    <affiliation>Fairview University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 2, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>chronic congenital neutropenia</keyword>
  <keyword>chronic neutropenia</keyword>
  <keyword>congenital pure red cell aplasia</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>neutropenia</keyword>
  <keyword>pure red cell aplasia</keyword>
  <keyword>rare disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>thalassemia major</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Red-Cell Aplasia, Pure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

